NCT03865927View on ClinicalTrials.gov

GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
OTHER

Placebo Oral Tablet

see Arm/Group description

DRUG

GKT137831

GKT137831 is a NOX enzyme inhibitor

Trial Locations (4)

19140

Temple University Medical Center, Philadelphia

35233

University of Alabama at Birmingham, Birmingham

48109

University of Michigan Medical Center, Ann Arbor

70112

Tulane University Medical Center, New Orleans

All Listed Sponsors
collaborator

Temple University

OTHER

collaborator

Tulane University

OTHER

collaborator

University of Michigan

OTHER

lead

University of Alabama at Birmingham

OTHER

NCT03865927 - GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter